英文互译镜像站

Linrodostat

Last updated
Linrodostat
Linrodostat.svg
Clinical data
Other namesBMS-986205; ONO 7701
Routes of
administration 		Oral
Legal status
Legal status
  • Investigational
Identifiers
  • (2R)-N-(4-Chlorophenyl)-2-[(1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide
CAS Number
DrugBank
ChemSpider
UNII
Chemical and physical data
Formula C24H24ClFN2O
Molar mass 410.92 g·mol−1
3D model (JSmol)
  • FC1=CC=2C(=CC=NC2C=C1)[C@@H]3CC[C@]([C@H](C(NC4=CC=C(Cl)C=C4)=O)C)(CC3)[H]
  • InChI=1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)/t15-,16-,17+/m1/s1
  • Key:KRTIYQIPSAGSBP-ZACQAIPSSA-N

Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities. [1]

Linrodostat is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). [2] [3]

Linrodostat has entered clinical trials for a variety of cancer types including bladder cancer, head and neck cancer, endometrial cancer, gastric cancer, melanoma, liver cancer, non-small cell lung cancer, and solid tumors. [4]

References

  1. ↑ "Linrodostat". NCI Drug Dictionary. National Cancer Institute.
  2. ↑ Balog A, Lin TA, Maley D, Gullo-Brown J, Kandoussi EH, Zeng J, Hunt JT (March 2021). "Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor". Molecular Cancer Therapeutics. 20 (3): 467–476. doi: 10.1158/1535-7163.MCT-20-0251 . PMID   33298590. S2CID   228087398.
  3. ↑ "IDO Inhibitor Development Shows Fresh Signs of Life Across Tumor Types". onclive.com. October 31, 2019.
  4. ↑ "Linrodostat". Adis Insight. Springer Nature Switzerland AG.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
关键词转码站群 站点克隆软件 YES镜站站群引擎 蚪侠镜像站群 干扰字符镜像